Inderscience launches nine new peer-reviewed journals - 28 Feb 2006
Scientific publisher Inderscience Publishers, Switzerland, has announced the launch of nine new peer-reviewed journal titles. The quarterly journals are available in print and online at http://www.inderscience.com.
The new titles are: International Journal of Productivity and Quality Management (IJPQM); International Journal of Electronic Finance (IJEF); International Journal of Information Systems and Change Management (IJISCM); International Journal of Knowledge Management Studies (IJKMS); International Journal of Metadata, Semantics and Ontologies (IJMSO); International Journal of Value Chain Management (IJVCM); International Journal of Modelling, Identification and Control (IJMIC); International Journal of Nuclear Governance, Economy and Ecology (IJNGEE); and International Journal of Agile Systems and Management (IJASM).
Inderscience, a publisher of peer-reviewed international journals in the fields of engineering and technology, management and business administration, and energy, environment and sustainable development, has launched nearly 50 titles in 2005 and 2006. With the addition of the nine new titles, the total number of published titles will increase to more than 130.
Nature forms publishing partnership with 'Australasian Society for Immunology' - 28 Feb 2006
Nature Publishing Group (NPG), UK, has partnered with the Australasian Society for Immunology (ASI), Australia, to jointly publish the Society's flagship journal, Immunology and Cell Biology (ICB), starting January 2007.
This partnership is part of a major initiative of NPG Nature Asia-Pacific, under which the company will partner with scientific societies in this region to produce high-quality journals. A bi-monthly, ICB will now join NPG's highly respected journals in Immunology and Molecular Cell Biology. This includes Nature Immunology, Nature Cell Biology, Nature Reviews Immunology, The EMBO Journal and Genes and Immunity. The journal will benefit from NPG's editorial expertise, pioneering technologies, innovative formats and world-class production to provide premium information for scientific researchers in the public and private sectors, government agencies and educators.
Click here to read the original press release.
Sunshine Media unveils Sacramento version of MD News - 28 Feb 2006
B2B information provider Sunshine Media Inc, US, has announced the forthcoming launch of the Sacramento edition of its free magazine, MD News. The journal is slated for launch in April 2006.
Published exclusively for professionals in the healthcare industry, M.D. News provides wide editorial coverage on hospice care, medicare reform, technology, genetics and alternative medicine. Each edition profiles a physician or practice in the industry, and features new products, services and innovations. The journal claims to be an essential tool for medical doctors (MDs), osteopathic doctors (DOs), podiatrists (DPM), hospital administrators and medical specialists.
This is the company's second title in Sacramento version. It first launched the Sacramento edition of its b2b magazine Builder/Architect in May 2005.
Sunshine Media publishes over 1,000 local editions and claims to have a readership of nearly 400,000 in the medical, dental, commercial building, residential building, real estate and restaurant industries in the US and Canada.
Venture capital group bid for VNU set to be tabled - 28 Feb 2006
7 billion bid by a consortium of seven venture capital firms for media group VNU NV, Netherlands, is likely to be submitted in the middle of this week, it has been reported. The consortium, comprising Carlyle, Blackstone, Thomas H Lee, Alpinvest, Hellman & Friedman, Permira and KKR, had offered to acquire VNU for €
28- 28.50 per share in January 2006. The portfolio to be acquired includes business information titles such as Hollywood Reporter and Adweek.
It is expected that the bid will not cross the originally proposed non-binding offer of €
28.5 per share. The takeover is likely to be welcomed by shareholders who had expressed unhappiness with the existing management. They had vetoed the VNU board's proposal to acquire US-based market research firm IMS Health for $7 billion.
The consortium bid is viewed as attractive, since it may keep the media group together. Also, a new management team can turn the business around. According to sources, the consortium intends to retain the business for up to six years, growing organically and through acquisitions.
Scope named to KMWorld's '100 Companies that Matter in Knowledge Management' - 28 Feb 2006
Database and research services provider Scope e-Knowledge Center, India, has announced that it has been named as one of the '100 Companies that Matter in Knowledge Management' by KMWorld, a leading information provider serving the Knowledge, Document and Content Management systems market. The KMWorld 100 recognises companies that best exemplify the ideals of true knowledge management.
An integrated business information & Knowledge Management Organisation, Scope e-Knowledge offers a range of remote knowledge services, which include business research, abstraction and indexing (A&I) and creating Scientific & Technical databases. The company also provides patent drafting, search, and patent related services.
With over 400 employees and offices in New York, London, Brussels, Cologne and Chennai, the company offers the unique concept of "assisted automation " - the combination of technology with use of domain specialists to create databases and other intellectual property that are of enduring value to clients. Scope's clients include leading print and online publishing companies, patent offices, corporate organisations, legal firms and a host of information intermediaries in the U.S. U.K. and Europe.
A publishing unit of Information Today, Inc., KMWorld serves the Knowledge, Document and Content Management systems market.
Sequencing, recreating 1918 Spanish flu virus wins Lancet's Paper of the year 2005 - 28 Feb 2006
British medical journal The Lancet has announced that two papers on the characterisation of the 1918 Spanish influenza pandemic virus have won The Lancet's Paper of the Year 2005. Published in scientific journals Science and Nature, the papers were announced winners following a vote conducted among members of Lancet's international advisory board and its editors.
The paper titled 'Characterization of the 1918 influenza virus polymerase genes' published in Nature, describes the final three genes of the 1918 human influenza virus, which is thought to have killed up to 50 million people. While authors of the other winning paper 'Characterization of the reconstructed 1918 Spanish influenza pandemic virus' published in Science, used the full genome sequence to recreate the virus and study its effects in mice.
The papers were authored by 16 researchers from the US Armed Forces Institute of Pathology, the US Centers for Disease Control, the department of microbiology at Mt. Sinai School of Medicine in New York and the US Department of Agriculture's Southeast Poultry Research Laboratory.
'New England Journal of Medicine' report on denosumab for BMD increase - 28 Feb 2006
Biotechnology company Amgen, US, has announced that the New England Journal of Medicine has published the results of a one-year study, according to which a prescribed dosage of denosumab is beneficial for bone mineral density (BMD). Biannual injections of denosumab, a RANK Ligand inhibitor, significantly increased BMD in the total hip, lumbar spine, distal 1/3 radius and total body compared to placebo. This data is published in the February 23 issue of the journal.
Researchers reported that subcutaneous injections of denosumab significantly increased BMD at the total hip from 1.9 to 3.6 percent in women who were administered the therapy twice yearly as compared with a decrease of 0.6 percent in the placebo group at one year.
Denosumab targets RANK Ligand, a protein that acts as the primary mediator of osteoclast (cells that break down bone) activity. This investigational therapy is the first RANK Ligand inhibitor in late stage development.
In the one-year trial results, researchers reported twice-yearly subcutaneous injections of denosumab significantly increased lumbar spine BMD from 3.0 to 6.7 percent after 12 months as compared with a decrease of 0.8 percent in the placebo-treated patients. The incidence of adverse events was similar among the denosumab, placebo and FOSAMAX groups, with the exception of dyspepsia. Dyspepsia occurred in 7 percent of placebo patients, 6-15 percent of denosumab patients and 26 percent of open-label FOSAMAX patients.
Click here to read the original press release.